Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects

Trial Profile

Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2011

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Atherosclerosis; Coronary disorders; Hyperlipidaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2011 Planned number of patients changed from 15 to 55.
    • 16 Jun 2011 New trial record
    • 01 May 2011 Results published in Clinical Drug Investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top